The immune system: a target for functional foods?

Philip C. Calder* and Samantha Kew

Institute of Human Nutrition, School of Medicine, University of Southampton, Bassett Crescent East, Southampton SO16 7PX, UK

The immune system acts to protect the host from infectious agents that exist in the environment (bacteria, viruses, fungi, parasites) and from other noxious insults. The immune system is constantly active, acting to discriminate ‘non-self’ from ‘self’. The immune system has two functional divisions: the innate and the acquired. Both components involve various blood-borne factors (complement, antibodies, cytokines) and cells. A number of methodologies exist to assess aspects of immune function; many of these rely upon studying cells in culture ex vivo. There are large inter-individual variations in many immune functions even among the healthy. Genetics, age, gender, smoking habits, habitual levels of exercise, alcohol consumption, diet, stage in the female menstrual cycle, stress, history of infections and vaccinations, and early life experiences are likely to be important contributors to the observed variation. While it is clear that individuals with immune responses significantly below ‘normal’ are more susceptible to infectious agents and exhibit increased infectious morbidity and mortality, it is not clear how the variation in immune function among healthy individuals relates to variation in susceptibility to infection. Nutrient status is an important factor contributing to immune competence: undernutrition impairs the immune system, suppressing immune functions that are fundamental to host protection. Undernutrition leading to impairment of immune function can be due to insufficient intake of energy and macronutrients and/or due to deficiencies in specific micronutrients. Often these occur in combination. Nutrients that have been demonstrated (in either animal or human studies) to be required for the immune system to function efficiently include essential amino acids, the essential fatty acid linoleic acid, vitamin A, folic acid, vitamin B6, vitamin B12, vitamin C, vitamin E, Zn, Cu, Fe and Se. Practically all forms of immunity may be affected by deficiencies in one or more of these nutrients. Animal and human studies have demonstrated that adding the deficient nutrient back to the diet can restore immune function and resistance to infection. Among the nutrients studied most in this regard are vitamin E and Zn. Increasing intakes of some nutrients above habitual and recommended levels can enhance some aspects of immune function. However, excess amounts of some nutrients also impair immune function. There is increasing evidence that probiotic bacteria improve host immune function. The effect of enhancing immune function on host resistance to infection in healthy individuals is not clear.


The immune system

Introduction

The immune system acts to protect the host from infectious agents that exist in the environment (bacteria, viruses, fungi, parasites) and from other noxious insults. The immune system is constantly active, acting to discriminate ‘non-self’ from ‘self’. The immune system has two functional divisions: the innate (or natural) immune system and the acquired (also termed specific or adaptive) immune system. Both components of immunity involve various blood-borne factors (complement, antibodies, cytokines) and cells. These cells are generally termed leucocytes (or white blood cells). Leucocytes fall into two broad categories: phagocytes (which include granulocytes (neutrophils, basophils, eosinophils), monocytes and macrophages) and lymphocytes. Lymphocytes are classified as T lymphocytes, B lymphocytes and natural killer cells. T lymphocytes are further divided into helper T cells (these are distinguished by the presence of the

Abbreviations: DTH, delayed-type hypersensitivity; IFN-γ, interferon-γ; Ig, immunoglobulin; IL, interleukin; MHC, histocompatibility complex; TNF, tumour necrosis factor.

* Corresponding author: Dr P. C. Calder, fax +44 23 8059 4383, email pcc@soton.ac.uk
molecule CD4 on their surface) and cytotoxic T cells (these are distinguished by the presence of CD8 on their surface). All cells of the immune system originate in bone marrow. They are found circulating in the bloodstream, organised into lymphoid organs such as the thymus, spleen, lymph nodes and gut-associated lymphoid tissue, or dispersed in other locations around the body.

**Innate and acquired immunity**

Innate immunity is the first line of defence against infectious agents. It is present prior to exposure to pathogens and its activity is not enhanced by such exposures. Innate immunity is concerned with preventing entry of infectious agents into the body and, if they do enter, with their rapid elimination. Elimination can occur by:

1. direct destruction of pathogens by complement, by toxic chemicals (e.g. superoxide radicals and hydrogen peroxide) released by phagocytes or by toxic proteins released by natural killer cells;
2. engulfing pathogens by the process of phagocytosis, which is made more efficient by coating the invading pathogen with host proteins like complement or antibodies, and their subsequent destruction.

Acquired immunity involves the specific recognition of molecules (antigens) on an invading pathogen, which distinguish it as being foreign to the host. The recognition of antigens is by antibodies (immunoglobulins (Ig) produced by B lymphocytes) and by T lymphocytes. T lymphocytes are only able to recognise antigens displayed on cell surfaces. Therefore, infection of a cell by an intracellular pathogen is signalled to T lymphocytes by cell surface expression of peptide fragments derived from the pathogen. These fragments are transported to the surface of the infected cell and expressed there in conjunction with proteins termed major histocompatibility complex (MHC); in man MHC is termed human leucocyte antigen. It is the combination of the pathogen-derived peptide fragment bound to MHC that is recognised by T lymphocytes. There are two classes of MHC, MHC I and MHC II, and the source of the peptide bound to each differs. MHC I binds peptides that originate from pathogen proteins synthesised within the host cell cytosol; typically these are from viruses or certain bacteria. The peptides bound to MHC II are derived from pathogens that have been phagocytosed by macrophages or endocytosed by antigen-presenting cells (macrophages, dendritic cells, B lymphocytes). The MHC–peptide complex is recognised by the T cell receptor on T lymphocytes. T lymphocytes expressing CD8 recognise MHC I, while T lymphocytes expressing CD4 recognise MHC II. Thus, intracellular pathogens stimulate cytotoxic T lymphocytes to destroy the infected cell, while extracellular pathogens stimulate a helper T cell-mediated response.

The acquired immune system includes a component of memory, such that if the antigen is encountered again (i.e. there is re-infection) the response is faster and stronger than the initial response. Although the immune system as a whole can recognise tens of thousands of antigens, each lymphocyte can recognise only one antigen and so the number of lymphocytes specific for a particular antigen must be very low. However, when an antigen is encountered it binds to the small number of lymphocytes that recognise it and causes them to divide so as to increase the number of cells capable of mounting a response to the antigen; this is the process termed lymphocyte expansion or proliferation. B lymphocytes proliferate and mature into antibody-producing cells (plasma cells) and T lymphocytes proliferate and are able directly to destroy virally infected cells (cytotoxic T lymphocytes) or control the activity of other cells involved in the response (helper T cells). The B lymphocyte response to antigen is termed humoral immunity and the T cell response is termed cell-mediated immunity.

**Integration of the immune response**

Communication within the acquired immune system and between the innate and acquired systems is brought about by direct cell-to-cell contact involving adhesion molecules and by the production of chemical messengers. Chief among these chemical messengers are proteins called cytokines, which can act to regulate the activity of the cell that produced the cytokine and/or of other cells. Each cytokine can have multiple activities on different cell types. Cytokines act by binding to specific receptors on the cell surface and thereby induce changes in growth, development or activity of the target cell.

When an immunological stimulus is encountered, the innate response, including its inflammatory component, responds initially, acting directly to eliminate it by the activities of complement, phagocytosis, etc. Cytokines (e.g. tumour necrosis factor-α (TNF-α), interleukin (IL)-1 and IL-6) produced by the cells involved in the innate response, especially monocytes and macrophages, will regulate this response and also act systemically on the liver to promote acute phase protein synthesis, on skeletal muscle and adipose tissue to promote proteolysis and lipolysis, respectively (this is believed to be the body’s way of providing fuels to the immune system) and on the brain to reduce appetite and induce fever. These cytokines will also interact with T lymphocytes. Antigen-presenting cells, which include activated monocytes and macrophages, will present antigen to T lymphocytes and so the acquired immune response will be triggered. Now there will be a cell-mediated response to the antigen. T lymphocytes will produce cytokines which will regulate the activity of the cells involved in the innate response (monocytes, macrophages, natural killer cells), promote the proliferation of B and T lymphocytes and promote antibody production by B lymphocytes. By virtue of the integrated innate and acquired responses the source of the antigen should be eliminated and a component of immunological memory will remain (Fig. 1).

**Biomarkers of immune function**

There is a wide range of methodologies by which to assess the immune response and the impact of nutrient supply on immune function (for a discussion see Cunningham-Rundles, 1998). Assessments can be made of cell functions
**ex vivo** (i.e. of the isolated cells outside the body and studied in short- or long-term culture), of indicators of immune function **in vivo** (e.g. by measuring the concentrations of proteins relevant to immune function in the bloodstream), of responses to an immunological challenge (e.g. inoculation with an antigen, a vaccine or live bacteria) or, in human studies, of the incidence and severity of infectious diseases. Clearly, animals offer greater access to the immune system, but it is important that observations made in animal studies be confirmed in man. Although **ex vivo** measures of immune function are made frequently, changes in these may not necessarily result in an altered immune response **in vivo**. Thus, in order to ascertain the effect of an intervention on the immune response, measures reflecting **in vivo** activity of the immune system are superior to **ex vivo** measures. However, the two approaches should be used in combination to understand better the mechanism of impact of an intervention.

**Ex vivo measures**

Animal studies often investigate the functions of immune cells isolated from the blood, thymus, spleen, lymph nodes, peritoneal cavity and, in some cases, from the bone marrow, lungs, liver and gastrointestinal tract. Human studies are more limited and routinely only the blood pool is sampled. In some cases other sources of human immune cells have been studied: for example, studies of asthma and respiratory illness often use cells collected by bronchoalveolar lavage. Measures of immune function that can be made on cells cultured **ex vivo** include:

1. Phagocytosis of bacteria, sheep red blood cells or yeast particles by neutrophils, monocytes and macrophages; this can be coupled with measures of bacterial killing.
2. Respiratory burst (superoxide generation) by neutrophils, monocytes and macrophages in response to

---

**Fig. 1. Integration of the immune response.**
Measures of immune function that reflect in vivo activity include:

1. Size of lymphoid organs.
2. Cellularity of lymphoid organs.
3. Number and types of immune cells circulating in the bloodstream.
4. Cell surface expression of molecules involved in antigen presentation (e.g. MHC) and in cellular activation (e.g. cytokine receptors).
5. Circulating concentration of thymulin and its activity.
6. Circulating concentrations of Ig specific for antigens after an antigen challenge.
7. Concentration of secretory IgA in saliva, tears and intestinal washings.
8. Cytokine concentrations in saliva and gut lavage.

In vivo measures

Measures of immune function that reflect in vivo activity include:

1. Resistance to challenge with live pathogens; the outcome is usually survival, although this can be coupled with some of the above measures and with measures of the numbers of pathogens found in various organs (e.g. spleen, lymph nodes, liver). This has been used in animal experiments.
2. Delayed-type hypersensitivity (DTH) response to extrinsic application of an antigen to which the individual has already been exposed; this measures the cell-mediated immune response. The response is measured as the size of the swelling (termed induration) around the area of application at a period (usually forty-eight hours) after the application.
3. Natural killer cell activity, measured as killing of virally infected cells known to be specific targets for natural killer cells.
4. Cytotoxic T lymphocyte activity, measured as killing of virally infected cells known to be specific targets for cytotoxic T cells.
5. Lymphocyte proliferation. This is the increase in number of lymphocytes in response to a stimulus. Most often this is measured as the incorporation of radioactively labelled thymidine into the DNA of the dividing lymphocytes, although a number of other measures are available. Agents used to stimulate lymphocyte proliferation include concanavalin A and phytohaemagglutinin, which stimulate T lymphocytes. These agents are all known as mitogens and the process as mitogen-stimulated lymphocyte proliferation. If the individual has been sensitised to an antigen (or allergen), then the antigen can be used to stimulate lymphocyte proliferation.
6. Production of cytokines by lymphocytes, monocytes and macrophages. This usually requires the cells to be stimulated. For lymphocytes, mitogens (or antigens, if the individual has been sensitised) are used, while for monocytes and macrophages bacterial lipopolysaccharide is most often used.
7. Production of total or specific Ig by lymphocytes.
8. Cell surface expression of molecules involved in antigen presentation (e.g. MHC) and in cellular activation (e.g. cytokine receptors).
9. Concentration of secretory IgA in saliva and gut lavage.
10. Delayed-type hypersensitivity (DTH) response to intradermal application of an antigen to which the individual has already been exposed; this measures the cell-mediated immune response. The response is measured as the size of the swelling (termed induration) around the area of application at a period (usually forty-eight hours) after the application.
11. Resistance to challenge with live pathogens; the outcome is usually survival, although this can be coupled with some of the above measures and with measures of the numbers of pathogens found in various organs (e.g. spleen, lymph nodes, liver). This has been used in animal experiments.

In vitro studies

In addition to the above approaches, which can be used to assess the impact of a nutrient supplied in the diet on immune function, in vitro studies adding the nutrient in pure form directly to immune cells in culture can be used. Each of the cell functions listed above under ‘ex vivo measures’ can be studied in this way. In vitro studies use conditions that are highly controlled, although they are often rather unphysiological in nature. For example, the cells are cultured in isolation from the other types of cell that they would come into contact with in the body (this is also a problem with many ex vivo measures) and the concentrations of the pure nutrient added to the cultures are often greatly in excess of those that can be attained in vivo. Also, the exact form of the nutrient added directly to cell cultures might be different from the form that is available to the cells in vivo. Nevertheless, in vitro studies are useful to identify the potential effects of dietary components and to study their mechanisms of action. However, it is necessary that effects identified in in vitro studies be confirmed in controlled dietary studies.

There is significant inter-individual variation in immune biomarkers

Variation in cellular immune responses among individuals is not a great problem in animal studies since these most often use inbred strains. However, it is important to note that some responses do differ among animal species and even among different strains within a species. It is possible that immune cells from different species and strains will exhibit different sensitivities to the amount of a nutrient in the diet. Thus, extrapolations from animal studies to man should be made cautiously. There is wide variation in immune cell responses among healthy human subjects (Table 1; see also Yaqoob et al. 1999), and immune responses can be affected by the presence of disease. Individuals with deficient immune responses are more susceptible to infectious agents and suffer greater morbidity and mortality as a result of infections. Such individuals have one or more key immune responses that fall below the threshold that represents ‘normality’. However, it is not at all clear whether variation in immune responses within the ‘normal’ range results in variable susceptibility to infection. Understanding the relationship between the variations in immune responses and in susceptibility to infection is complicated by a number of other factors. For example, vaccination is widely used to prime the immune system to efficiently eliminate certain pathogens that may or may not exist in the environment at some later stage, antibiotics are used widely to help the host
Table 1. Variation in immune responses among healthy human subjects. Blood was collected from healthy human volunteers (aged 40 to 60 years) in the fasting state. Phagocytosis and oxidative burst in response to Escherichia coli were determined in whole blood by flow cytometry (see Thies et al. 2001a); data are expressed as the % of active cells. Mononuclear cells (a mixture of lymphocytes and monocytes) were prepared using standard procedures and were cultured under standard conditions in the presence of either bacterial lipopolysaccharide (LPS; 15 μg/ml) or concanavalin A (Con A; 25 μg/ml; see Yaqoob et al. 2000; Thies et al. 2001b). After 24 h of culture, the concentrations of cytokines in the cell culture supernatants were measured by specific ELISA (see Yaqoob et al. 2000; Thies et al. 2001a, b). LPS was used to stimulate production of tumour necrosis factor-α (TNF-α), interleukin (IL)-1β and IL-6, while Con A was used to stimulate the production of IL-2, interferon-γ (IFN-γ) and IL-4. Lymphocyte proliferation was determined as the incorporation of [3H]thymidine over the last 18 h of a 66 h culture period (see Yaqoob et al. 2000; Thies et al. 2001b); data are expressed as cpm of thymidine incorporated/2 × 10⁵ cells in the initial culture.

<table>
<thead>
<tr>
<th>Cell type</th>
<th>Function</th>
<th>Range</th>
<th>Mean</th>
<th>SD</th>
<th>n</th>
<th>Range</th>
<th>Mean</th>
<th>SD</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutrophil</td>
<td>Phagocytosis of E. coli (% of cells)</td>
<td>41–93</td>
<td>73</td>
<td>16</td>
<td>50</td>
<td>12–95</td>
<td>73</td>
<td>21</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>Oxidative burst to E. coli (% of cells)</td>
<td>68–98</td>
<td>90</td>
<td>7</td>
<td>56</td>
<td>67–98</td>
<td>90</td>
<td>7</td>
<td>40</td>
</tr>
<tr>
<td>Monocyte</td>
<td>Phagocytosis of E. coli (% of cells)</td>
<td>3–47</td>
<td>21</td>
<td>11</td>
<td>51</td>
<td>4–46</td>
<td>20</td>
<td>10</td>
<td>37</td>
</tr>
<tr>
<td></td>
<td>Oxidative burst to E. coli (% of cells)</td>
<td>76–98</td>
<td>92</td>
<td>4</td>
<td>50</td>
<td>45–99</td>
<td>91</td>
<td>9</td>
<td>37</td>
</tr>
<tr>
<td></td>
<td>TNF-α production (ng/ml)</td>
<td>1.2–48.8</td>
<td>11.1</td>
<td>7.9</td>
<td>83</td>
<td>1.0–43.6</td>
<td>10.5</td>
<td>6.4</td>
<td>57</td>
</tr>
<tr>
<td></td>
<td>IL-1β production (ng/ml)</td>
<td>0.5–14.5</td>
<td>5.0</td>
<td>3.3</td>
<td>78</td>
<td>0.3–17.4</td>
<td>5.5</td>
<td>3.7</td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>IL-6 production (ng/ml)</td>
<td>0.9–83.8</td>
<td>36.5</td>
<td>21.3</td>
<td>72</td>
<td>1.5–73.7</td>
<td>33.7</td>
<td>21.6</td>
<td>52</td>
</tr>
<tr>
<td>Lymphocyte</td>
<td>Proliferation (cpm/2 × 10⁵ cells)</td>
<td>4753–70583</td>
<td>32241</td>
<td>14612</td>
<td>80</td>
<td>4024–73058</td>
<td>31747</td>
<td>16666</td>
<td>57</td>
</tr>
<tr>
<td></td>
<td>IL-2 production (IU/ml)</td>
<td>2.2–43.7</td>
<td>8.5</td>
<td>6.1</td>
<td>82</td>
<td>1.3–28.1</td>
<td>8.3</td>
<td>6.0</td>
<td>56</td>
</tr>
<tr>
<td></td>
<td>IFN-γ production (IU/ml)</td>
<td>4.2–641</td>
<td>127.3</td>
<td>131</td>
<td>76</td>
<td>2.4–578.9</td>
<td>117.7</td>
<td>120</td>
<td>53</td>
</tr>
<tr>
<td></td>
<td>IL-4 production (pg/ml)</td>
<td>3.5–485.7</td>
<td>69.6</td>
<td>81.2</td>
<td>82</td>
<td>3.0–389.9</td>
<td>49.9</td>
<td>64.3</td>
<td>60</td>
</tr>
</tbody>
</table>

sd, standard deviation.
of the nutrient to be studied in a highly controlled setting, and because the immune system of experimental animals is more accessible than that of man. In man, studies of the immunological impact of nutrient deficiencies have been imposed by habitual consumption of diets deficient in one or more nutrients, or, more rarely, through individuals with diseases that result in inability to absorb nutrients. These studies have made it clear that there are a number of nutrients whose availability at an appropriate level is essential if the immune response is to operate efficiently. Nutrients that have been demonstrated (in either animal or human studies) to be required for the immune system to function efficiently include essential amino acids, the essential fatty acid linoleic acid, vitamin A, folic acid, vitamin B6, vitamin B12, vitamin C, vitamin E, Zn, Cu, Fe and Se (for reviews see Gross & Newberne, 1980; Chandra, 1991; Kuvibidila et al. 1993; Scrimshaw & SanGiovanni, 1997; Calder & Jackson, 2000). Practically all forms of immunity may be affected by deficiencies in one or more of these nutrients and the deficient animal or individual becomes more susceptible to infections. Animal and human studies have demonstrated that adding the deficient nutrient back to the diet can restore immune function and resistance to infection (for reviews see Chandra, 1991; Scrimshaw & SanGiovanni, 1997; Calder & Jackson, 2000).

**Vitamin E and zinc: well researched examples of the impact of the dietary supply of micronutrients on immune function**

**Vitamin E.** Vitamin E is the major lipid-soluble antioxidant in the body and is required for protection of membrane lipids from peroxidation. Since free radicals and lipid peroxidation are immunosuppressive, it is considered that vitamin E should act to optimise and even ‘enhance’ the immune response (for reviews see Bendich, 1993; Meydani & Beharka, 1998). The effects of vitamin E depletion are more marked if animals are fed a diet containing a high level of polyunsaturated fatty acids (Corwin & Schloss, 1980). Vitamin E deficiency increases susceptibility of animals to infectious pathogens (for references see Meydani & Beharka, 1998). Vitamin E supplementation of the diet of laboratory animals enhances antibody production, lymphocyte proliferation, natural killer cell activity, and macrophage phagocytosis (for references see Meydani & Beharka, 1998). Adding vitamin E to the diet of aged mice increased lymphocyte proliferation, IL-2 production and the DTH response (Meydani et al. 1986). A high level of vitamin E in the diet (500 mg/kg food) also increased natural killer cell activity of spleen cells from old, but not young, mice (Meydani et al. 1988). Dietary vitamin E promotes resistance to pathogens in chickens, turkeys, mice, pigs, sheep and cattle (for references see Meydani & Beharka, 1998; Han & Meydani, 1999); some of these studies report improved immune cell functions in the animals receiving additional vitamin E (Han & Meydani, 1999). Vitamin E prevented the retrovirus-induced decrease in production of IL-2 and interferon-γ (IFN-γ) by spleen lymphocytes and in natural killer cell activity in mice (Wang et al. 1994). In another study, young and old mice were fed diets containing adequate (30 mg/kg diet) or high (500 mg/kg diet) levels of vitamin E for 6 weeks and infected with influenza A virus. Young or old mice fed the high level of vitamin E had lower lung titres of virus than old mice fed the adequate vitamin E diet (Hayek et al. 1997). The high level of vitamin E caused increased production of IL-2 and IFN-γ by spleen lymphocytes from influenza-infected old mice (Han et al. 1998). These observations suggest that increasing vitamin E intake above habitual levels might enhance immune function and improve resistance and that vitamin E supplementation might be particularly beneficial in the elderly.

Studies in man also suggest a relationship between vitamin E supply and immune function. Canadian 3-year-olds with the lowest serum vitamin E levels had the lowest lymphocyte proliferative responses and serum IgM concentrations (Vobecky et al. 1984). Chavance et al. (1989)
found a positive association between plasma vitamin E levels and DTH responses, and a negative association between plasma vitamin E levels and incidence of infections, in healthy adults aged over sixty. Administration of vitamin E to premature infants enhanced neutrophil phagocytosis (Baehner et al. 1977; Chirico et al. 1983) but decreased the ability of neutrophils to kill bacteria (Baehner et al. 1977); this latter effect is most likely due to a vitamin E-induced decrease in the production of free radicals and related reactive species. Supplementation of the diet of elderly subjects with 800 mg vitamin E/d for 4 weeks increased lymphocyte proliferation, IL-2 production and the DTH response, but did not affect IL-1 production, the number of CD4\(^+\) cells or circulating Ig concentrations (Meydani et al. 1990). In a more recent study, 60, 200 and 800 mg vitamin E/d increased the DTH response in elderly subjects, with 200 mg/d having the maximal effect (Fig. 3; Meydani et al. 1997). The 200 mg/d dose increased the antibody responses to hepatitis B, tetanus toxoid and pneumococci vaccinations (Fig. 3; Meydani et al. 1997). In some cases the 800 mg vitamin E/d supplement decreased the antibody response to below that of the placebo group (Fig. 3). The authors concluded that 200 mg of vitamin E daily represents the optimal level for the immune response. Some studies report that high levels of vitamin E in the human diet (>300 mg/d) decrease the ability of neutrophils to undergo phagocytosis (Boxer, 1986) and to kill bacteria (Baehner et al. 1977; Prasad, 1980) and decrease monocyte respiratory burst and IL-1\(\beta\) production (Devaraj et al. 1996).

**Zinc.** Zn deficiency in animals is associated with a wide range of immune impairments (for reviews see Fraker et al. 1993; Wellingshausen et al. 1997; Shankar & Prasad, 1998). Zn deficiency has a marked impact on bone marrow, decreasing the number of nucleated cells and the number and proportion of cells which are lymphoid precursors (for reviews see Fraker et al. 1993; Fraker & King, 1998). In patients with Zn deficiency related to sickle cell disease, natural killer cell activity is decreased, but can be returned to normal by Zn supplementation (Tapazoglou et al. 1985). In acrodermatitis enteropathica, which is characterised by reduced intestinal Zn absorption, thymic atrophy, impaired lymphocyte development, decreased numbers of CD4\(^+\) cells and reduced lymphocyte responsiveness and DTH are observed (Chandra & Dayton, 1982; Fraker et al. 1986). Moderate or mild Zn deficiency or experimental Zn deficiency (induced by Zn consumption of <3·5 mg/d; habitual intakes among adults in the UK are 9 to 12 mg/d) in man results in decreased thymulin activity, decreased natural killer cell activity, a lowered CD4\(^+\):CD8\(^+\) ratio, and decreased lymphocyte proliferation, IL-2 production and DTH response; all can be corrected by Zn repletion (Shankar & Prasad, 1998). Experimental Zn deficiency in man decreased IL-2, IFN-\(\gamma\) and TNF-\(\alpha\) production by mitogen-stimulated lymphocytes but did not affect IL-4, IL-6 or IL-10 production by these cells or IL-1\(\beta\) production by lipopolysaccharide-stimulated cells (Beck et al. 1997).

Low plasma Zn levels predicted the subsequent development of lower respiratory tract infections and diarrhoea among Indian infants (Bahl et al. 1988). Indeed, diarrhoea is considered a symptom of Zn deficiency. Malnourished, Zn-deficient children given Zn (2 mg/kg body weight daily for 10 days) had increased thymus size as judged by radiography (Golden et al. 1977). Topical application of Zn to malnourished children improved the DTH response in the area of skin on which the application was made (Golden et al. 1978). Zn administration (2 mg/kg body weight daily) to malnourished children decreased the incidence of diarrhoea by more than 50\%, decreased the incidence of respiratory and skin infections, and resulted in threefold increased growth compared with children given low-dose Zn (3·5 mg daily; Castillo-Duran et al. 1987). There are now a number of studies showing that Zn supplementation decreases the incidence of childhood diarrhoea and respiratory illness (for references see Scrimshaw & SanGiovanni, 1997; Shankar & Prasad, 1998; Calder &...
Jackson, 2000), although some studies fail to show benefit of Zn supplementation in respiratory disease (for references see Calder & Jackson, 2000). As well as decreasing the risk of young infants developing diarrhoea (Rosado et al. 1997), Zn supplementation (20 mg/d) to malnourished children reduced diarrhoea-induced growth faltering (Roy et al. 1999). Zn administration to preterm low-birth-weight infants (1 mg/kg daily for 30 days) increased the number of circulating T lymphocytes and lymphocyte proliferation (Chandra, 1991). Providing 5 mg Zn/d to low-birth-weight, small-for-gestational-age infants for 6 months increased measures of cell-mediated immune function and decreased the incidence of gastrointestinal and upper respiratory tract infections (Lira et al. 1998); a Zn dose of 1 mg/d was without effect.

As observed for vitamin E, excessive Zn intakes impair immune responses. For example, giving 300 mg Zn/d for 6 weeks to young adult human subjects decreased lymphocyte and phagocyte function (Chandra, 1984). High Zn intakes can result in Cu depletion, and Cu deficiency impairs immune function (for reviews see Prohaska & Failla, 1993; Failla & Hopkins, 1998).

**Probiotics: functional food components that impact on immune function**

Indigenous bacteria are believed to contribute to the immunological protection of the host by creating a barrier against colonisation by pathogenic bacteria. This barrier can be disrupted by disease and by use of antibiotics, so allowing easier access of the host gut by pathogens. It is now believed that this barrier can be maintained by providing supplements containing live ‘desirable’ bacteria: such supplements are called probiotics (for extensive reviews see Goldin, 1998; Naidu *et al.* 1999). Probiotic organisms are found in fermented foods, including traditionally cultured dairy products and newer kinds of fermented milks. The organisms included in commercial probiotics include lactic acid bacteria (*Lactobacillus acidophilus*, *Lactobacillus casei*, *Enterococcus faecium*) and *Bifidobacterium* spp. These organisms colonise the gut only temporarily and so their regular consumption is necessary. In addition to creating a barrier effect, some of the metabolic products of probiotic bacteria (e.g. lactic acid and a class of antibiotic proteins termed bacteriocins, produced by some bacteria) may inhibit growth of pathogenic organisms (Fig. 4). Also, the desirable bacteria may compete for nutrients with the pathogens (Fig. 4). Finally, there is some evidence that probiotic bacteria may enhance the gut immune response against pathogenic bacteria (Fig. 4).

Studies in rats and mice reveal that lactic acid bacteria administered orally increase the numbers of T lymphocytes, CD4+ cells and antibody-secreting cells, including those in the intestinal mucosa, and enhance lymphocyte proliferation, natural killer cell activity, IL-1, TNF and IFN-γ production, antibody production (including secretory IgA), phagocytic activity and the respiratory burst of macrophages and the DTH response (for a review see Naidu *et al.* 1999). However, not all strains of lactic acid bacteria are equally effective (Naidu *et al.* 1999). Animal studies also show that orally administered lactic acid bacteria protect against challenges with pathogenic bacteria such as *Salmonella typhimurium*, reverse some of the immunosuppressive effects of malnutrition and cause the symptoms of enterocolitis to be less severe (Naidu *et al.* 1999). Co-colonisation of rats with

---

**Fig. 4.** Potential roles of probiotic bacteria in the human intestinal tract. Probiotic bacteria may act in a variety of ways to prevent the growth and colonisation of pathogenic bacteria.
Lactobacillus plantarum and Escherichia coli resulted in higher circulating concentrations of total IgA and of E. coli-specific IgA and IgM than if the rats were colonised with E. coli alone; there was also increased expression of the IL-2 receptor in the lamina propria (Herias et al. 1999).

Despite the extensive animal studies, the effects of probiotic bacteria on human immune function are still controversial (Naidu et al. 1999). However, several studies in man have reported an enhancement in markers of immune function following probiotic administration.

Healthy Japanese children consuming a probiotic formula containing bifidobacteria had increased faecal levels of total and anti-poliovirus IgA prior to taking the formula (Fukushima et al. 1998). Healthy adults consuming probiotic bacteria showed enhanced phagocytosis by neutrophils and monocytes (Schiffrin et al. 1997; Yoon et al. 1999). Adults fed fermented milk containing lactobacilli and bifidobacteria and exposed to S. typhimurium showed increased total and S. typhimurium-specific IgA concentrations in their serum (Link-Amster et al. 1994). Administration of probiotic bacteria reduced the incidence and severity of diarrhoea in children attending daycare centres and the duration of diarrhoea in infants hospitalised with gastroenteritis; in some studies this was associated with an increase in levels of IgG, IgA and IgM and in anti-rotavirus IgA secreting cells in the bloodstream (for references see Naidu et al. 1999). Probiotic bacteria have also been shown to reduce the incidence of antibiotic-induced diarrhoea in children (Arvola et al. 1999; Vanderhoof et al. 1999). Although some studies have shown that consumption of probiotics can protect against traveller’s diarrhoea, other studies do not demonstrate such protection (for references see Naidu et al. 1999).

The immune system as a target for functional foods?

As described earlier, deficiency of total energy or of one or more essential nutrients impairs immune function and increases susceptibility to infectious pathogens. This is most likely because these nutrients are involved in the molecular and cellular responses to challenge of the immune system. Providing these nutrients to deficient individuals restores immune function and improves resistance to infection. For some nutrients (e.g. vitamin E) the dietary intakes that result in greatest enhancement of immune function are greater than recommended intakes. However, excess intake of some nutrients (e.g. vitamin E, Zn) also impairs immune responses. Thus, four potential general relationships appear to exist between the intake of a nutrient and immune function (Fig. 5). These different types of relationship might in part reflect interactions between nutrients such that an excess of one nutrient negatively affects the status of a second nutrient (e.g. vitamin E).
Zn and Cu). There are likely to be interactions between similar classes of nutrients (e.g. \( n - 6 \) and \( n - 3 \) polyunsaturated fatty acids) that have yet to be unravelled fully, and there are most likely interactions between nutrients which contribute to oxidative stress (e.g. polyunsaturated fatty acids) and those which protect against it (e.g. vitamin E).

It is often assumed when defining the relationship between nutrient intake and immune function that all components of the immune system will respond in the same dose-dependent fashion to a given nutrient. This is not correct, at least as far as some nutrients are concerned, and it appears likely that different components of the immune system show an individual dose–response relationship to the availability of a given nutrient (Fig. 6). Indeed, some immune functions might be relatively insensitive to nutrient supply.

Some consider that the immune system does not respond optimally to challenge in apparently healthy, free-living human individuals even if they are not deficient in any single nutrient. Individuals may be marginally deficient in one or more nutrients or they may be consuming some nutrients (e.g. fat) in excess. There is now much interest in optimising the immune response in such individuals not simply by correcting marginal deficiencies but by increasing the intake of certain nutrients and probiotics. At this stage the immune-enhancing effect of such supplementation is generally unproven. Indeed, as far as micronutrients are concerned, such supplementation might even be dangerous. Before the immune system can be considered a genuine target for functional foods, more needs to be known about the role of variation in the immune response among apparently healthy individuals in determining their susceptibility to infection; about the influence of altered supply of specific nutrients and of nutrient combinations on aspects of immune function in different populations; about the impact of genotype, gender, age and early life experiences on immune function and on determining the sensitivity of the immune system to nutrients; and, most importantly, about whether enhanced immune responses really translate into increased resistance to infection.

Acknowledgements

The experimental results shown in Table 1 are taken from a research project supported by the Ministry of Agriculture Fisheries and Food, the Biotechnology and Biological Sciences Research Council, Hoffman-La Roche and Unilever Research Vlaardingen under the Agri-Food LINK Program (Grant Number AFQ111). The authors are indebted to Miss T. Banerjee and to collaborators at the Hugh Sinclair Unit of Human Nutrition, School of Food Biosciences, University of Reading for their role in this research.

References


Fraker PJ, King LE, Garvy BA & Medina CA (1993) The immunopathology of zinc deficiency in humans and rodents:


